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Abstract: We synthesized eight new bipyridine and bipyrimidine gold (III) dithiocarbamate-containing
complexes (C1–C8) and tested them in a panel of human cancer cell lines. We used osteosarcoma
(MG-63), lung (A549), prostate (PC3 and DU145), breast (MCF-7), ovarian (A2780 and A2780cis,
cisplatin- and doxorubicin-resistant), and cervical (ME-180 and R-ME-180, cisplatin resistant) cancer
cell lines. We found that C2, C3, C6, and C7 were more cytotoxic than cisplatin in all cell lines
tested and overcame cisplatin and doxorubicin resistance in A2780cis and R-ME-180 cells. In the PC3
prostate cancer cell line, the gold (III) complex C6 ([Au2(BPM)(DMDTC)2]Cl4) induced apoptosis
and double-stranded DNA breaks, modified cell cycle phases, increased Reactive Oxigen Species
(ROS) generation, and reduced thioredoxin reductase and proteasome activities. It inhibited PC3 cell
migration and was more cytotoxic against PC3 cells than normal human adipose-derived stromal
cells. In mice bearing PC3 tumor xenografts, C6 reduced tumor growth by more than 70% without
causing weight loss. Altogether, our results demonstrate the anticancer activity of these new gold
(III) complexes and support the potential of C6 as a new agent for prostate cancer treatment.
Keywords: gold (III) complexes; anticancer therapy; cisplatin resistance; doxorubicin resistance;
prostate cancer
1. Introduction
Cisplatin and a few related platinum compounds, such as carboplatin and oxaliplatin, are common
anticancer agents [1,2], but their use often causes significant toxicity and leads to drug resistance [3,4].
Therefore, other metallodrugs [5] containing platinum or non-platinum metals, such as ruthenium,
palladium, titanium, gold, and copper, have been investigated [6–8]. In particular, gold (I) and gold (III)
complexes have been widely studied and found to have anticancer effects in vitro and in vivo [5,8,9].
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Gold (I) and gold (III) complexes have a variety of mechanisms of action [9], including inhibition of
the enzyme thioredoxin reductase (TrxR), increased generation of reactive oxygen species (ROS) [10,11],
proteasome inhibition [12], interaction with DNA [13], alteration of the cell cycle phases [14], and
modulation of kinases [15]. These multifaceted modes of action enable gold complexes to exert potent
cytotoxicity against cancer cells, including multidrug-resistant tumor cells [5,9]. However, gold and
other heavy metals such as platinum also react with the sulfur-containing amino acids cysteine (a thiol)
and methionine (a thioether), generating metal-protein adducts that can be nephrotoxic [9].
One way to prevent interactions between the metal center of anticancer drugs and thiol-containing
biomolecules is to use dithiocarbamate as a chelating ligand. Through its sulfur atoms,
dithiocarbamate coordinates metal ions, thereby stabilizing metal drugs and reducing interactions with
biomolecules [5,16]. Some of us reported that gold (III) dithiocarbamate complexes had potent in vitro
anticancer activity against acute myeloid leukemia cells [11] and prostate cancer cells [17] and low
toxicity in tumor-bearing mice [17]. To improve the delivery and cellular uptake of these compounds,
we designed a second generation of gold (III) dithiocarbamate complexes [18]. These molecules,
called peptidomimetics, are derivatives of oligopeptides, and they were designed to target the peptide
transporters PEPT1 and PEPT2 that are upregulated in several tumor types. The compounds showed
promising anticancer activity in different tumor models [18], including breast [19] and prostate
cancer [20].
In parallel research, a team led by Altaf designed and synthesized other metallodrugs with
anticancer activity, including gold (I) [21,22] and gold (III) complexes [23]. Together, our two research
groups produced new bipyridine gold (III) dithiocarbamate complexes with nitrogen and sulfur donor
ligands [24]. The new gold (III) complexes were cytotoxic in cisplatin-resistant ovarian carcinoma cells
as well as in p53-defective cancer cells of different tumor types, and compound 1 was shown to be less
cytotoxic in non-cancer human mesenchymal stromal cells than in cancer cells [24]. To improve upon
the antitumor properties of gold (III) analogs, we synthesized eight new gold (III) dithiocarbamate
complexes with bipyridine or bipyrimidine ligands. Here, we report the synthesis, chemical analysis,
and anticancer activity of these new gold (III) complexes (C1–C8). We screened the compounds
on a panel of human cancer cell lines, including doxorubicin- and cisplatin-resistant cells, and
evaluated the mechanism of action and the in vivo anticancer activity of the most active compound C6
([Au2(BPM)(DMDTC)2]Cl4) against PC3 prostate cancer cells.
2. Results
The expected structures of eight new gold (III) compounds (C1–C8) are shown in Figure 1.
Four molecules (compounds C1–C4) have a 2,2′-bipyridine-3,3′-diol (BPYH) moiety and a single gold
atom, while the others (compounds C5-C8) have a 2,2′-bipyrimidine (BPM) moiety and two gold
atoms. Compounds C2 and C6 are dimethyldithiocarbamates, C3 and C7 are diethyldithiocarbamates,
and C4 and C8 are dibenzyldithiocarbamates. The gold (III) complexes had >99% purity and interacted
with lysozyme, tryptophan, and guanine (Supplementary Materials, Figures S1–S10 and Tables S1–S3).
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Figure 1. Chemical structures of the eight new gold (III) complexes (compounds C1–C8). BPYH,
2,2′-bipyridine-3,3′-diol; BPM, 2,2′-bipyrimidine; DMDTC, dimethyldithiocarbamate; DEDTC,
diethyldithiocarbamate; DBDTC, dibenzyldithiocarbamate.
2.1. In Vitro Cytotoxicity of Gold (III) Complexes
To evaluate the potential anticancer activity of the eight compounds, we first compared their
in vitro cytotoxicity to that of cisplatin in a panel of cell lines derived from different human cancers
including lung cancer (A549), androgen-sensitive prostate cancer (DU145), androgen-resistant prostate
cancer (PC3), breast cancer (MCF-7), and osteosarcoma (MG-63) (Table 1).
Cisplatin had relatively low potency on three cell lines (A549, MCF-7, and MG-63), with half
maximal inhibitory concentrations (IC50) >10 µM, while it was more potent on the DU145 and PC3
prostate cancer cell lines with mean IC50 values of 4.5 µM and 3.3 µM, respectively. Compound C1
had IC50 values higher than that of cisplatin in most cell lines, indicating lower potency, while in
MG-63 the two drugs had similar activities. Compounds C2 and C3 were more potent than cisplatin
in all cell lines and had IC50 values more than one order of magnitude lower than cisplatin in the
cisplatin-resistant MCF-7, A549, and MG-63 cell lines. Compounds C4 and C8 were less cytotoxic than
cisplatin in PC3 and DU145 cells but more cytotoxic than cisplatin in MCF-7, A549, and MG-63 cells.
Compound C5 exerted very low cytotoxic effects on most cell lines except for MG-63. Compound C6
and C7 had submicromolar IC50 values in almost all cell lines, and thus were the most potent of all
compounds tested, including cisplatin.
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Table 1. Half-maximal inhibitory concentrations (IC50) of cisplatin and new gold (III) compounds in
human lung, prostate, breast, and osteosarcoma cancer cell lines. Values are mean (SD) expressed
in µM.
Compound
Cell Line
A549 DU145 PC3 MCF-7 MG-63
Cisplatin 52.0 (4.7) 4.5 (0.4) 3.3 (0.3) 22.2 (0.2) 58.0 (0.5)
C1 >80 39.0 (3.5) 28.3 (2.6) 59.0 (5.3) 43.0 (3.9)
C2 6.1 (0.6) 2.8 (0.3) 1.5 (0.1) 2.3 (0.2) 3.8 (0.3)
C3 3.8 (0.3) 3.5 (0.3) 1.3 (0.1) 1.7 (0.2) 1.2 (0.1)
C4 25.0 (2.3) 6.4 (0.6) 8.5 (0.8) 13.0 (1.2) 12.3 (1.1)
C5 >80 >80 >80 65.0 (5.9) 26.0 (2.3)
C6 0.8 (0.1) 0.7 (0.1) 0.6 (0.1) 0.5 (0.1) 0.8 (0.1)
C7 1.4 (0.1) 0.8 (0.1) 0.8 (0.1) 0.6 (0.1) 0.7 (0.1)
C8 23.0 (2.1) 22.8 (2.1) 19.5 (1.8) 9.5 (0.9) 5.8 (0.5)
The cytotoxic effects of the gold (III) compounds were also evaluated in two cell lines for which a
cisplatin-resistant clone was available. First, in the ovarian cancer cell line A2780 (cisplatin sensitive),
compounds C2, C3, C6, and C7 were more potent than cisplatin (i.e., they had IC50 values <1.5 µM),
whereas compounds C1, C4, C5, and C8 were less potent (Table 2).
Table 2. Half-maximal inhibitory concentrations (IC50) of reference drugs and gold (III) compounds
in ovarian cancer cell line A2780 and its cisplatin- and doxorubicin-resistant A2780cis clone and fold
resistance (FR).
Compound
IC50, µM a
FR (A2780cis/A2780)
A2780 A2780cis
Cisplatin 1.5 (0.1) 10.4 (0.9) 6.9
Doxorubicin 0.02 (0.0) 0.12 (0.0) 9.0
C1 23.0 (2.1) 24.0 (2.0) 1.0
C2 0.9 (0.1) 0.8 (0.1) 0.9
C3 0.4 (0.0) 0.4 (0.0) 1.1
C4 7.3 (0.7) 8.2 (0.7) 1.1
C5 15.4 (1.4) 16.2 (5.1) 1.1
C6 0.2 (0.0) 0.3 (0.0) 1.2
C7 0.4 (0.0) 0.3 (0.0) 0.9
C8 3.8 (0.3) 5.2 (0.5) 1.4
a Mean (SD).
In the cisplatin- and doxorubicin-resistant clone A2780cis, the IC50 of each gold (III) compound
was similar to that in the parental cell line, but because the IC50 of cisplatin was higher, compounds C2,
C3, C4, C6, C7, and C8 were all more potent than the reference drug. The fold resistance (FR) between
the two cell lines (IC50 A2780cis/IC50 A2780) was 6.9 for cisplatin and 9.0 for doxorubicin, while for
the eight test compounds it was close to unity (range, 0.9 to 1.4). This result excludes the phenomenon
of cross-resistance to these two drugs in these cell lines.
A similar experiment was carried out using the ME-180 cervical cancer cell line and its
cisplatin-resistant clone R-ME-180 (Table 3). In ME-180 cells, compounds C2, C3, C6, and C7 were
more potent than cisplatin (i.e., they had IC50 values <15 µM), and compounds C1, C4, and C5 were
less active. In R-ME-180 cells, the IC50 value for cisplatin was higher, giving FR = 4.5. The FR for the
test compounds (excluding C5) was lower, ranging from 0.9 (C7) to 1.5 for C2.
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Table 3. Half-maximal inhibitory concentrations (IC50) of cisplatin and gold (III) compounds in cervical
cancer cell line ME-180 and its cisplatin-resistant R-ME-180 clone and fold resistance (FR).
Compound
IC50, µM a
FR (R-ME-180/ME-180)
ME-180 R-ME-180
Cisplatin 15.0 (1.4) 68.0 (6.1) 4.5
C1 70.0 (6.3) 72.0 (6.5) 1.0
C2 14.0 (1.3) 21.0 (1.9) 1.5
C3 3.0 (0.3) 3.8 (0.3) 1.3
C4 30.0 (2.5) 30.0 (2.7) 1.0
C5 >80 >80 ND
C6 5.3 (0.5) 4.9 (0.5) 0.9
C7 4.8 (0.4) 4.1 (0.4) 0.9
C8 15.0 (1.4) 16.0 (1.4) 1.0
ND, not determined. a Mean (SD).
Then, we examined the cellular uptake of the gold (III) compounds. PC3 cells were incubated
separately with two low-potency compounds C4 and C5 and two high-potency compounds C6 and
C7, and the amount of internalized gold was determined using mass spectrometry (Figure S11).
This analysis showed greater uptake of the two more potent molecules, with C6 internalization even
greater than that of C7.
To further investigate the cytotoxicity of C6 ([Au2(BPM)(DMDTC)2]Cl4 ), we compared its effects
on growth of PC3 cells and normal human adipose-derived stromal cells. This analysis showed that
C6 was more potent in the prostate tumor cells (IC50 = 0.6 µM) than in the normal stromal cells
(IC50 = 1.4 µM) (Figure S12).
Altogether, these experiments show that compounds C2, C3, C6, and C7 have the greatest potency
(lowest IC50 values) in the panel of investigated tumor cell lines. Results from pairs of cell lines
that differ in susceptibility to cisplatin (ME-180 and R-ME180) and also to doxorubicin (A2780 and
A2780cis) rule out cross-resistance to the two chemotherapy agents.
2.2. Cellular Mechanism of Action of Compound C6
C6 was chosen for further analyses with the PC3 prostate cancer cell line. When PC3 cells were
incubated with C6 at IC50 (0.62 µM) and IC75 (1.85 µM), there was a dose-dependent increase in the
percentage of annexin-V-positive cells, indicating early apoptosis, and also of double stained annexin-V-
and propidium iodide (PI)-positive cells, indicating late apoptosis (Figure 2A,B). Consistently,
treatment with C6 activated caspase 3,7, evaluated using fluorochrome-labeled inhibitors of caspases
(FLICA) that irreversibly bind active caspase (Figure 2C,D). These results suggest that apoptosis is
involved in tumor cell death by C6. Finally, treatment of PC3 cells with C6 modified the distribution
of cells in the cell cycle, by increasing the percentage of cells in S phase and decreasing that in G1
compared to untreated cells (Figure 2E,F).
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Figure 2. C6 induces apoptosis and blocks the cell cycle. PC3 cells were cultured in complete
medium alone or with C6, at the half-maximal inhibitory concentration (IC50), at IC25, or IC75, for 24 h.
(A,B) Annexin-V-FITC and propidium iodide (PI) assay of apoptosis by flow cytometry. (A) Percentage
of annexin-V-positive cells. (B) Representative flow cytometry plots; the percentages of stained cells are
reported. (C,D) Caspase 3,7 activation assay evaluated using flow cytometry with fluorochrome-labeled
inhibitors of caspases (FLICA). (C) Mean fluorescence intensity (MFI) of FLICA. (D) Representative
flow cytometry histograms of caspase 3,7 activation by C6 treatment. The percentage of FLICA-positive
cells is reported. (E,F) Cell cycle progression determined by PI staining. (E) Percentage distribution
of cells in different cell cycle phases. (F) Representative flow cytometry histograms of cell cycle
progression. All bar charts report means and SD of three independent experiments. Statistical analysis
was performed using one-way ANOVA, followed by Dunnett’s multiple comparisons test. * p < 0.05
vs. medium.
Next, we determined if C6 treatment led PC3 cells to increase the production of reactive oxygen
species (ROS). Two concentrations of C6 induced ROS production in a dose-dependent manner, and
this effect was blocked when cells were pretreated with N-acetyl cysteine (NAC), a ROS scavenger
(Figure 3A,B).
NAC decreased the cytotoxic effects of C6 (Figure 3C), suggesting that ROS generation is
involved in this compound’s cytotoxicity. Treatment of PC3 cells with C6 also induced, in a time- and
dose-dependent manner, double-stranded DNA breaks, as shown by an increase in phosphorylation
of histone H2A.X (Figure 3D,E). We did not observe H2AX phosphorylation at the early time points
(Figure 3D,E). Because ROS elimination and the maintenance of intracellular redox balance depend on
the thioredoxin (Trx) system [25], we examined the effects of C6 used at IC25 (0.31 µM), IC50 (0.62 µM),
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and IC75 (1.85 µM) on Trx reductase (TrxR) levels and found that a short incubation resulted in a
dose-dependent decrease of its enzymatic activity (Figure 3F). Finally, C6 exerted a dose-dependent
inhibitory effect also on 20S proteasome activity (Figure 3G).
Figure 3. Compound C6 increases ROS generation induces double-stranded DNA breaks and reduces
thioredoxin reductase and 20 S proteasome activities. PC3 cells were cultured in complete medium
alone or with compound C6, at the half-maximal inhibitory concentration (IC50), at IC25, or IC75.
(A,B) Reactive oxygen species (ROS) generation by PC3 cells exposed to C6 at IC50 and IC75 for
24 h, in the presence or absence of the ROS scavenger N-acetyl cysteine (NAC) (added 30 min before
drug treatment). ROS were detected using H2DCFDA. (A) Generated ROS levels (mean fluorescence
intensity, MFI). (B) Representative flow cytometry histograms of generated ROS. (C) Number of viable
cells 24 h after treatment with C6 and NAC (NAC, added 30 minutes before drug treatment), evaluated
using trypan blue dye exclusion. (D,E) Histone H2A.X phosphorylation (γH2A.X) as a measure of
double-stranded DNA breaks, detected with FITC anti-H2A.X Phospho (Ser139) antibody. (D) Time
course of phosphorylation at two concentrations of C6. (E) Representative flow cytometry histograms
of γH2A.X. (F) Thioredoxin reductase (TrxR) activity after a 12 h treatment with C6, normalized
to control (medium). (G) Proteasome activity after a 12 h treatment with C6, evaluated with the
20S-Proteasome Assay kit, normalized to control (medium). All bar charts report means and SD of
three independent experiments. Statistical analysis was performed using one-way ANOVA, followed
by Turkey’s or Dunnett’s multiple comparisons test where appropriate. * p < 0.05 vs. medium, unless
otherwise indicated.
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2.3. Effects of C6 on Tumor Cell Migration and Xenograft Growth
The effect of C6 on PC3 cell migration was evaluated using the in vitro scratch assay. A 3 h
pretreatment slowed the ability of PC3 cells to refill an empty area (“scratch”) of the monolayer
compared to untreated cells: 36 h after the monolayer was scratched, the remaining uncovered area
was about 40% in C6-pretreated cells and about 10% in control cells (Figure 4A,B). Finally, we examined
the effects of C6 on the in vivo growth of PC3 cell xenografts in female athymic nude mice. Inhibition
of tumor growth became apparent starting 15 days after the beginning of treatment, compared to
animals not treated with C6 (Figure 4C). By day 32, control tumors had grown to a mean volume of
1327 mm3 (SD = 105 mm3) whereas C6-treated tumors reached 385 mm3 (SD = 35 mm3), reflecting a 71%
inhibitory effect (Figure 4C). This difference was significant (p < 0.0001, Student’s t test). C6 treatment
did not affect the weight of the animals (Figure 4D).
Figure 4. Compound C6 reduces cell migration and PC3 tumor xenograft growth. (A,B) Scratch
assay. Confluent monolayers of PC3 cells were treated or not with compound C6 (IC50) for 3 h in
complete medium, “wounded” by scraping, then cultured in low serum medium and photographed
every 12 h for up to 36 h. (A) Cell-free area remaining over time as cells migrated into the wound,
normalized to time 0. Bar graph shows the mean and SD of three experiments each done in triplicate.
* p < 0.05, Student’s t test. (B) Representative phase contrast photomicrographs, original magnification
4×. (C) Growth of xenografts in nude mice inoculated with PC3 cells (3× 106 cells/animal) and treated
intratumorally with C6 (2.5 mg/kg) (n = 5) or vehicle (n = 5). Values are mean and SD. Student’s t test,
* p < 0.0001. (D) Body weights of xenografted mice (n = 5 per group).
3. Discussion
In this study, we evaluated the anticancer activity of new bipyridine and bipyrimidine
gold (III) complexes (C1–C8) using a panel of cancer cell lines. The eight new compounds
had potent cytotoxicity in ovarian, lung, breast, prostate, cervical and sarcoma cancer cell lines.
They were also active in a cisplatin-resistant cervical cell line (R-ME-180) and in a cisplatin- and
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doxorubicin-resistant ovarian cancer cell line (A2780cis), suggesting that they may overcome both
cisplatin and doxorubicin resistance.
The mechanism of action and the in vivo activity of the most active compound, C6, were
evaluated using androgen-resistant PC3 prostate cancer cells. C6 induced apoptosis, activated
caspases 3,7, and modified the distribution of cells in cell cycle phases. Moreover, C6 increased
ROS generation. ROS may play an important role in the cytotoxic effect of C6 since the ROS scavenger
NAC counteracted C6’s ability to inhibit cell growth. C6 treatment also induced double-stranded
DNA breaks. This DNA damage is more likely due to apoptosis induced by the increased intracellular
ROS levels [25] than to a direct effect of C6 on DNA. Thioredoxin (Trx) and the seleno-enzyme
thioredoxin reductase (TrxR) are essential components of the Trx system that regulates cellular redox
signaling pathways [25,26]. TrxR inhibition increases ROS accumulation, which causes mitochondrial
dysfunction and apoptosis [25]. High levels of Trx and TrxR have been found in many different tumor
types, including prostate cancer [27], and are associated with tumor progression and resistance to
several anticancer drugs, including cisplatin [28]. For these reasons, the Trx system may be a target for
cancer therapy [25,26]. TrxR has already been identified as an important target of several gold (I) (e.g.,
auranofin) [10,29] and gold (III) complexes [15,17,20]. Here we found that, consistently with increased
ROS generation, C6 inhibited TrxR enzymatic activity in PC3 cells.
The proteasome, a central component of the protein degradation machinery, controls the
expression of proteins linked to cell survival and proliferation [30]. Cancer cells produce anti-apoptotic
and pro-survival proteins, and their treatment with proteasome inhibitors causes cell cycle arrest or
apoptosis, suggesting their use in clinic [31]. Some gold (III) complexes have already been found to
target the proteasome in cancer cells [8,12,17,20,32,33], and here we found that C6 inhibited proteasome
activity in prostate cancer cells.
Since androgen-independent prostate cancer has high invasive potential, a successful therapeutic
approach should counteract not only tumor growth but also the metastatic potential [34]. Here, we
found that C6 reduced PC3 cell migration, suggesting that this gold (III) complex may inhibit not
only tumor proliferation, but also its dissemination. The adverse effects of C6 on cell migration may
be attributed to a decreased expression of molecules involved in PC3 cell migration or to decreased
growth of treated cells.
Some studies of metal-based compounds, including gold (III) complexes, have found promising
in vitro cytotoxicity but did not test growth inhibition in in vivo experiments [8,35,36]. Therefore, we
evaluated the in vivo antitumor activity of C6. Consistent with our in vitro studies, C6 significantly
reduced PC3 tumor xenograft growth with low toxicity (measured as body weight change).
4. Materials and Methods
Methods for the synthesis and chemical characterization of the gold (III) complexes are described
in the Supplementary Materials, together with electrochemical methods for testing their interactions
with a protein, an amino acid, and a nucleobase and cellular methods for testing uptake
4.1. Drugs
Gold (III) complexes were dissolved in DMSO to 10 µM. The same amount of DMSO necessary to
dissolve the compounds was used as negative control in all experiments. Cisplatin and doxorubicin
were surplus drugs obtained from the pharmacy at Centro Riferimento Oncologico.
4.2. Cell Lines and Culture Conditions
Human androgen-resistant (PC3) and androgen-sensitive (DU145) prostate cancer cell lines were
obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig,
Germany). Human breast adenocarcinoma MCF-7 (HTB-22TM), lung cancer (A549), and osteosarcoma
(MG-63) cell lines were from the American Type Culture Collection (ATCC, Rockville, MD, USA).
Human ovarian epithelial carcinoma-derived A2780 cell line and its cisplatin- and doxorubicin-resistant
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clone A2780cis were from Sigma-Aldrich (Milano, Italy). The highly invasive cervical cancer-derived
ME-180 (HPV positive) cell line was a kind gift of Dr. G. Toffoli (CRO, Aviano, Italy), and the
cisplatin-resistant clone R-ME-180 was developed in our laboratory by continuous exposure to
1 µM cisplatin. Cell lines were tested for mycoplasma every 15 d using the MycoAlert test (Lonza,
Verviers, Belgium).
A549, MG-63, MCF-7, ME-180, and R-ME-180 cells were cultured in DMEM, and A2780, A2780cis,
PC3, and DU145 cells were cultured in RPMI-1640 medium; media contained 10% heat-inactivated fetal
bovine serum (FBS), 1% (v/v) of penicillin (10,000 units/mL)-streptomycin (10 mg/mL), and 1% (v/v)
L-glutamine (200 mM) (all from Sigma-Aldrich). R-ME-180 and A2780cis cells were maintained
in 1 µM cisplatin. Adipose-derived stromal cells were maintained in Mesenchymal-Stem-Cell
Growth Medium Bulletkit MSCGM (Lonza). All cell lines were cultured at 37 ◦C in a 5% CO2,
fully humidified atmosphere.
4.3. Cytotoxicity Assay
Cell lines were seeded in 96-well flat-bottomed microplates in 100 µL culture medium at the
following densities: DU145, PC3, and MCF-7 cells (2.5 × 103 cells/well); A2780, A2780cis, ME-180,
R-ME-180, and A549 cells (4.0 × 103 cells/well); and MG-63 cells (2.0 × 103 cells/well). Cells were
allowed to adhere for 24 h. Then, the medium was replaced with fresh medium alone or with
one of the gold (III) compounds at increasing concentrations from 0 to 100 µM. The reference drugs
cisplatin (0–100 µM) and doxorubicin (0–1 µM) were included as positive controls for growth inhibition.
After 72 h, cell viability was assayed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. All experimental conditions were tested in triplicate and the experiment was
done three times.
Half maximal inhibitory concentrations (IC50, the concentration required for 50% in vitro
inhibition of growth) and IC25 and IC75 values were calculated for each experiment using CalcuSyn
software (Version 2, Biosoft, Ferguson, MO, USA) [37]. IC50 values were reported as mean (SD).
For drug-resistance cell lines, fold resistance (FR) was calculated as the ratio of the IC50 of the resistant
cell line to the IC50 of the parental cell line.
4.4. Cellular Assays
In all cellular assays, PC3 cells (2.0 × 105 cells/well in six-well plates) were incubated in complete
culture medium containing different concentrations of compound C6 (IC25 = 0.31 µM, IC50 = 0.62 µM,
IC75 = 1.85 µM). All experimental conditions were tested in triplicate and experiments were done three
times to calculate means and SD.
For apoptosis assays, PC3 cells were treated with C6 for 24 h and then apoptosis was assayed
by staining for 15 min with FITC Annexin V reagent (BD Bioscences, Milano, Italy) and propidium
iodide (PI). Apoptotic cells were detected using flow cytometry (BD FACSCanto II flow cytometer) and
analyzed using BD FACSDiva v8.0.1 software (BD Biosciences, Milano, Italy). Caspase 3,7 activation
was evaluated using fluorochrome-labeled inhibitors of caspases (FLICA) of the CaspaTag Caspase 3,7
In Situ Assay Kit, Fluorescein (Chemicon-Millipore International, Milan, Italy) and evaluated using
flow cytometry; data were expressed as mean fluorescence intensity.
To assay the distribution of cells in the various phases of the cell cycle, PC3 cells were treated
with C6 for 48 h, then harvested, fixed in cold 70% ethanol for 15 min, and stained with PI solution
(50 µg/mL PI, 0.1% NP-40, 100 µg/mL PureLink RNase A, 0.1% sodium citrate (Sigma-aldrich, Milano,
Italy). After 1 h, cells were analyzed using flow cytometry. The distribution of cells in different cell cycle
phases was quantified using ModFit LT 4.0 software (BD Biosciences, Milano, Italy). The production
of reactive oxygen species (ROS) was evaluated using 2′,7′-dichlorodihydrofluorescein diacetate
(H2DCFDA) (H2-DCF, DCF) (Invitrogen, Monza, Italy). Cells were pretreated with the antioxidant
N-acetyl-L-cysteine (NAC; 5 mM) (Sigma, Milano, Italy) for 30 min before C6 was added. After 24 h of
C6 treatment, cells were harvested, and viable cells were counted using trypan blue dye exclusion.
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Then, cells were washed, stained with 1 µM H2DCFDA for 30 min at 37 ◦C, and finally ROS production
was analyzed using flow cytometry.
The presence of double-stranded DNA breaks was assessed 3, 6, 12, and 24 h after treatment with
C6 by fixing and permeabilizing cells with Fix & Perm medium A and B (Invitrogen) and staining with
FITC anti-H2A.X Phospho (Ser139) Antibody (BioLegend, San Diego, CA, USA). Stained cells were
evaluated using flow cytometry.
Thioredoxin reductase (TrxR) (EC 1.8.1.9) was assayed using the Thioredoxin Reductase Assay
Kit (Sigma-Aldrich). Cells were treated with C6 for 12 h and then lysed in 50 mM Tris-HCl pH 7.6,
0.1% Triton X-100, 0.9% NaCl. Enzyme activity was determined reading absorbance at 412 nm using
a spectrophotometer (Biomate 3 Thermo Spectronic, Thermo Electonic Corporation, Monza, Italy).
The enzymatic activity was normalized to the protein concentration, determined using the Bio-Rad
protein assay (Protein Assay Dye Reagent Concentrate, Bio-Rad Laboratories, Segrate, Italy), and
expressed as percentage of control (no C6).
Proteasome activity (EC 3.4.25.1) was evaluated on the same cell lysates as used to assay TrxR.
Proteasome activity was assayed in cytosolic extracts using the 20S Proteasome Activity Assay kit
APT280 (Merck Millipore) and a computer-interfaced GeniusPlus microplate reader (Tecan Trading
AG, Switzerland). The activity was normalized to the protein concentration, determined using the
Bio-Rad protein assay, as expressed as percentage of control.
Cell migration was assessed using the in vitro scratch assay. Briefly, cells were grown to confluence
and then treated with C6 (IC50). After 3 h, monolayers were washed twice with PBS, scraped with a
pipette tip to create a “wound” in the monolayer, and washed again. Culture medium with 2% (not
10%) FBS was added and the cells were cultured for 36 h. Wounds were photographed every 12 h using
an inverted microscope (EclipseTS/100, Nikon, Instruments Europe BV Amsterdam, Netherlands) at
magnification 4×. Migration was assessed by measuring the cell-free area (in pixels) with ImageJ-NIH
(National Institutes of Health) tool software after 12, 24, and 36 h.
4.5. Human Prostate Tumor Xenograft Experiments
Animal experiments were approved by the Italian Ministry of Health (no. 671/2015/PR).
Ten 4-week-old female athymic nu/nu (nude) mice were purchased from Envigo (Udine, Italy).
PC3 cells (3 × 106 in a 0.1 mL solution of Matrigel 1:3 in PBS) were inoculated subcutaneously into
the right flank of each mouse. Body weight and tumors were measured three times a week, and
tumor volumes were calculated according to the formula: (width2 × length × 3.14)/6. When tumors
reached a volume of ca. 120 mm3, mice were divided into two groups of five animals each. Mice were
treated every other day with an intratumoral injection of 2.5 mg/kg C6 or an equal volume of vehicle
(10% DMSO, 20% Cremophor Sigma-Aldrich, 70% PBS). Mice were killed on day 32 when control
tumors had reached about 1300 mm3.
4.6. Statistical Analysis
Statistical analysis was performed using GraphPad Prism v6 software (GraphPad Software,
San Diego, CA, USA). Student’s t test was used to compare two groups, and one-way analysis of
variance (ANOVA) was used for three or more groups; consecutive multiple comparisons were
performed using Dunnett’s or Tukey’s test. p < 0.05 indicated statistical significance.
5. Conclusions
These promising results represent a starting point for further preclinical testing of these new gold
(III) complexes. Additional research is needed to reveal the mechanism of action and to document
the in vivo activity of the active gold (III) complexes (C2, C3, C6, and C7), in other cancer models and
especially in cisplatin- or doxorubicin-resistant ones.
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